0001415889-24-009272.txt : 20240327
0001415889-24-009272.hdr.sgml : 20240327
20240327200016
ACCESSION NUMBER: 0001415889-24-009272
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240325
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Teehan Brendan
CENTRAL INDEX KEY: 0001891900
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 24792931
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-03272024_110355.xml
X0508
4
2024-03-25
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001891900
Teehan Brendan
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
false
true
false
false
EVP, COO, HEAD OF COMMERCIAL
0
Common Stock
2024-03-25
4
A
0
10048
0
A
41480
D
Common Stock
2024-03-27
4
S
0
5140
17.90
D
36340
D
Stock Options (Right to Buy)
17.84
2024-03-25
4
A
0
89516
0
A
2034-03-24
Common Stock
89516
89516
D
Restricted Stock Units
2024-03-25
4
A
0
27460
0
A
Common Stock
27460
27460
D
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target.
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The restricted stock units vest in four equal annual installments beginning March 25, 2025.
/s/ Jennifer J. Rhodes, Attorney-in-Fact
2024-03-27